The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules

• Published in: BMC complementary and alternative medicine 2019-01, Vol.19 (1), p.8-8, Article 8
• Main Authors: Dang, Yanqi, Hao, Shijun, Zhou, Wenjun, Zhang, Li, Ji, Guang
• Format: Article
• Language: English
• Subjects: Acetyl-CoA carboxylase; Asian medicine; Biochemistry; Blood; Blood lipids; Care and treatment; Chemical synthesis; Chinese medicine; Cholesterol; Chromophores; Diabetes; Diet; Fatty liver; Gene expression; Gene sequencing; Genes; Genetic aspects; Genomes; Genomics; Glucose metabolism; Glycogen; Glycogen metabolism; Glycogen phosphorylase; Glycogen synthase; Glycogen synthesis; Graphical user interface; Hepatology; Herbal medicine; High fat diet; Hydroxymethylglutaryl-CoA reductase; Hypoxia; Insulin; Intervention; Kinases; Laboratory animals; Ling-gui-zhu-Gan decoction; Lipid metabolism; Lipids; Lipogenesis; Liquor; Liver; Liver diseases; Measurement methods; Metabolic syndrome; Metabolism; Non-alcoholic fatty liver disease; Obesity; Oils & fats; Phosphatase; Phosphatases; Phosphoprotein phosphatase; Phosphorylase; Phosphorylation; Polysaccharides; PPP1R3C; Prevention; Protein binding; Protein phosphatase; Proteins; Regulation; Ribonucleic acid; RNA; RNA sequencing; Rodents; Steatosis; Steroids (Organic compounds); Sterol regulatory element-binding protein; Substrates; Traditional Chinese medicine; Triglycerides; Type 2 diabetes
• ISSN: 1472-6882; 1472-6882
• DOI: 10.1186/s12906-018-2424-1

Ling-gui-zhu-gan decoction (LGZG), a classic traditional Chinese medicine formula, has been confirmed to be effective in improving steatosis in non-alcoholic fatty liver disease (NAFLD). However, the mechanism under the efficacy remains unclear. Hence, this study was designed to investigate the mechanisms of LGZG on alleviating steatosis. Twenty four rats were randomly divided into three groups: normal group, NAFLD group, fed with high fat diet (HFD) and LGZG group (fed with HFD and supplemented with LGZG). After 4 weeks intervention, blood and liver were collected. Liver steatosis was detected by Oil Red O staining, and blood lipids were biochemically determined. Whole genome genes were detected by RNA-Seq and the significant different genes were verified by RT-qPCR. The protein expression of Protein phosphatase 1 regulatory subunit 3C (PPP1R3C) and key molecules of glycogen and lipid metabolism were measured by western blot. Chromophore substrate methods measured glycogen phosphorylase (GPa) activity and glycogen content. HFD can markedly induce hepatic steatosis and promote liver triglyceride (TG) and serum cholesterol (CHOL) contents, while liver TG and serum CHOL were both markedly decreased by LGZG treatment for 4 weeks. By RNA sequencing, we found that NAFLD rats showed significantly increase of PPP1R3C expression and LGZG reduced its expression. RT-qPCR and Western blot both verified the alteration of PPP1R3C upon LGZG intervention. LGZG also promoted the activity of glycogen phosphorylase liver type (PYGL) and inhibited the activity of glycogen synthase (GS) in NAFLD rats, resulting in glycogenolysis increase and glycogen synthesis decrease in the liver. By detecting glycogen content, we also found that LGZG reduced hepatic glycogen in NAFLD rats. In addition, we analyzed the key molecules in hepatic de novo lipogenesis and cholesterol synthesis, and indicated that LGZG markedly inhibited the activity of acetyl-CoA carboxylase (ACC), sterol receptor element-binding protein-1c (SREBP-1c) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), resulting in lipid synthesis decrease in the liver. Our data highlighted the role of PPP1R3C targeting pathways, and found that hepatic glycogen metabolism might be the potential target of LGZG in preventing NAFLD.